Henta 140 mill tidligere i år. Beregnet å holde godt ut i 2022.
1 Like
Episurf Medical (Nasdaq: EPIS B) will attend Digital Investor Forum on May 5 2020. The event is arranged by Redeye and the company will be represented by the CEO Pål Ryfors.
The presentation will be available live at 11:35 on https://www.redeye.se/events#/event/779848. The presentation will also be available after the conference at Redeyes website, as well as on the companys website.
1 Like
Etter å ha solgt ut posisjonen da aksjen stod i ca 7 SEK, så gjorde jeg mitt første kjøp, av forhåpentligvis flere, i Episurf i dag.
Selskapet har hentet penger, og selv om salget ikke har tatt helt av enda, så er det mye som tyder på at dette vil bli en suksess med tiden.
4 Likes
EPISURF MEDICAL
VD KÖPT AKTIER FLERA OMGÅNGAR SENASTE MÅNADEN (Direkt)
2020-05-06 11:43
STOCKHOLM (Nyhetsbyrån Direkt) Medicinteknikbolaget Episurf Medicals vd, Pål Ryfors, har under april och under början av maj vid flera tillfällen köpt aktier i bolaget. Senast på onsdagen gjordes ett köp.
Det framgår av ägardatatjänsten Holdings.
Under föregående månad har vd:n vid tre tillfällen ökat sitt innehav. Totalt har strax över 660.000 aktier förvärvats under april och maj, inkluderat ett fjärde köp på onsdagen.
Därmed summeras Pål Ryfors innehav till cirka 1,8 miljoner aktier i bolaget. Pål Ryfors ägande har därmed gått från 0,8 till 1,0 procent av kapitalet i Episurf Medical i och med köpen.
Köpen har gjorts till kurser om 1:39-1:62 kronor. På onsdagen vid 11.30-tiden handlades aktien till 1:63 kronor, vilket speglar en uppgång om 1,4 procent för dagen.
Flera styrelseledamöter har under de senaste veckorna också gjort insynsköp i Episurf.
4 Likes
Oppdatert analyse med høyere kursmål fra Redeye
4 Likes
Episurf Medical (NASDAQ: EPISB) today announces that the company has been informed by the authors about the submission to a scientific journal of the manuscript Patient-specific metal implants for focal chondral and osteochondral lesions in the knee - Excellent clinical results at 2 years. This manuscript covers results from a European multicentre study of the Episealer Knee implant with 75 patients.
This is wonderful news, and we are incredibly happy. We are now looking forward to seeing this paper published. The size of the study is several times larger than anything previously published on the Episealer, and this is undoubtedly a large study, says Pål Ryfors, CEO Episurf Medical.
5 Likes
Episurf Medical (NASDAQ: EPIS B) has received a Notice of Allowance from the Korean Intellectual Property Office (KIPO), implying the companys first patent approval in Korea. The patent, entitled System and method for creating a decision support material indicating damage to an anatomical joint covers Episurf Medicals 3D-based damage marking technology which constitutes a central part of the Episealer implant system as well as the Epioscopy joint visualisation system.
This is a core patent for Episurfs imaging technology. We are working towards being able to launch our products in certain Asian markets and maintaining a strong IP portfolio in relevant regions is an important part of that strategy, says Katarina Flodström, COO, Episurf Medical.
3 Likes
This is a multicenter, prospective study where patients that have undergone treatment with Episealer Knee have been followed to evaluate implant safety (revision rate) and clinical improvement score. The title of the manuscript speaks for itself:
“Patient-specific metal implants for focal chondral and osteochondral lesions in the knee – Excellent clinical results at 2 years”
To get these results in a scientific journal is a real milestone for the company. We expect that the results get published in H2’20. As we have stressed many times, clinical evidence is everything in this industry. And there is more to come in this regard throughout 2020.
4 Likes
Smeller det snart opp?
3 Likes
Det er mellomnavnet mitt 
5 Likes
The European patent office EPO has announced its intention to grant another European patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled System and method for creating a decision support material indicating damage to an anatomical joint, is within the area of 3D-based assessment of joint lesions, and complements the companys previously approved patents within that field.
Episurf Medicals damage marking technology constitutes a central part of the Episealer implant system as well as the Epioscopy joint visualisation system. Our visualisation of joint damage, which includes AI-based 3D-modelling, is unique and we are building a strong patent protection around it, says Katarina Flodström, COO, Episurf Medical.
1 Like
Tatt inn en post i dag, håper den faller litt mer til post 2 og 3 før opptur.
1 Like
The European patent office EPO has announced its intention to grant another European patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled System and method for optimising an implant position in an anatomical joint, covers parts of Episurf Medicals technology for optimised design of the individualised Episealer implants.
Episurf Medicals Episealer technology includes a number of details for optimised and efficient implant design, and this patent covers an important part thereof, comments Katarina Flodström, COO, Episurf Medical.
1 Like
Ble vist ferdig kjøpt i dag, så nå er det bare å lukke skuffen og vente 
2 Likes
EPISURF
Episurf är på gång med första Episealer-operationen i Asien-Stillahavsregionen (Finwire)
2020-06-12 10:23
Medicinteknikbolaget Episurf Medicals första operation med knäimplantatet Episealer i regionen Asien-Stillahavsregionen planeras.
“Detta är ett stort steg för oss och vi ser betydande möjligheter i regionen Asia Pacific. Vi har nyligen ökat vårt fokus mot ett antal nya marknader, där det regulatoriska arbetet fortlöper. Att vi gör vår första operation utanför Europa är verkligen spännande”, säger vd Pål Ryfors i ett pressmeddelande.
Stefan Linnér
stefan.linner@finwire.se
Nyhetsbyrån Finwire
3 Likes
18.6.2020, 12:45 · Cision
New Japanese patent approval for Episurf Medical
The Japanese patent office JPO has announced its intention to grant another Japanese patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled “System and method for creating a decision support material indicating damage to an anatomical joint”, is within the area of 3D-based assessment of joint lesions.
“This is a core patent for Episurf’s medical imaging technology, and we are happy to get it approved in strategically selected countries”, says Katarina Flodström, COO, Episurf Medical.
3 Likes
EPISURF
Episurf har börjat inkludera patienter i Nordamerika och Europa för IDE-studie (Finwire)
2020-06-23 10:06
Medicinteknikbolaget Episurf Medical har påbörjat inklusion av patienter i Nordamerika och Europa i bolagets kliniska IDE-studie för knäimplantatet Episealer. Det framgår av ett pressmeddelande.
“Denna registreringsgrundande studie är den enskilt största och viktigaste kliniska studien vi bedriver med tanke på att USA är världens i särklass största ortopediska marknad. Om vi i USA kan upprepa de fina kliniska resultat vi sett för Episealer i Europa, då står vi inför en mycket spännande framtid. Påbörjad patientrekrytering i IDE-studien är en milstolpe för oss”, säger vd Pål Ryfors.
Studien är en prospektiv, randomiserad, kontrollerad multicenterstudie med två års uppföljning av 180 patienter.
Stefan Linnér
stefan.linner@finwire.se
Nyhetsbyrån Finwire
3 Likes
Dette har vi ventet på lenge, når kommer første operasjonen i USA?
2 Likes